Sinupret s okusom trešnje sirup Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

sinupret s okusom trešnje sirup

bionorica se, kerschensteinerstraße 11-15, neumarkt, njemačka - tekući ekstrakt (1:5,6) iz mješavine korijena žutog srčanika, sporišove zeleni, štaveljove zeleni, bazgovog cvijeta i jaglačevog cvijeta s čaškom (1:3:3:3:3). ekstrakcijsko otapalo: etanol 59 % v/v - sirup - urbroj: 1 ml [odgovara 1,2 g] sirupa sadrži 0,05 ml tekućeg ekstrakta iz 11 mg mješavine gentiana lutea l., radix (korijen žutog srčanika), verbena officinalis l., herba (sporišova zelen), rumex l. sp., herba (štaveljova zelen), sambucus nigra l., flos (bazgov cvijet) i primula veris l. i/ili primula elatior hill, flos cum calycibus (jaglačev cvijet sa čaškom) (1:3:3:3:3); der 1:5,6; ekstrakcijsko otapalo: etanol 59 % (v/v)

Exviera Kesatuan Eropah - Croat - EMA (European Medicines Agency)

exviera

abbvie ltd - dasabuvir natrij - hepatitis c, kronični - antivirusni lijekovi za sustavnu uporabu - exviera je indicirana u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa c (chc) u odraslih osoba. virus hepatitisa c (hcv) genotip određene aktivnosti .

Equilis Prequenza Te Kesatuan Eropah - Croat - EMA (European Medicines Agency)

equilis prequenza te

intervet international bv - sojevi virusa influence konja: a / equine-2 / south africa / 4/03, a / equine-2 / newmarket / 2/93, tetanus toksoid - virus vozilima do konja gripe + клостридии - konji - aktivna imunizacija konja od šest mjeseci protiv influence konja zbog smanjenja kliničkih znakova i izlučivanja virusa nakon infekcije, te aktivne imunizacije protiv tetanusa radi sprječavanja smrtnosti.

Equilis Prequenza Kesatuan Eropah - Croat - EMA (European Medicines Agency)

equilis prequenza

intervet international bv - vozilima do konja gripe-sojevi virusa: a/konja 2/južna afrika/4/03 i/konja 2/newmarket/2/93 - virus vozilima do konja gripe - konji - aktivna imunizacija konja od šest mjeseci protiv influence konja za smanjenje kliničkih znakova i izolacije virusa nakon zaraze.

Maci Kesatuan Eropah - Croat - EMA (European Medicines Agency)

maci

vericel denmark aps - autologni kultivirani hondrociti - prijelom, hrskavica - ostali lijekovi za poremećaje mišićno-koštanog sustava - popravak simptomatskih oštećenja hrskavice koljena.

Reconcile Kesatuan Eropah - Croat - EMA (European Medicines Agency)

reconcile

forte healthcare limited - fluoksetin - psychoanaleptics - psi - kao pomoćno sredstvo u liječenju podjela ovisi o bolesti kod pasa se očituje uništavanja i neadekvatnih oblika ponašanja (govor i neprimjereno stolicu i / ili mokrenje), a tek u kombinaciji s bihevioralne modifikacije metode.

Zinbryta Kesatuan Eropah - Croat - EMA (European Medicines Agency)

zinbryta

biogen idec ltd - declizumaba - multipla skleroza - imunosupresivi - zinbryta je indicirana kod odraslih bolesnika za liječenje relapsnih oblika multiple skleroze (rms).

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Kesatuan Eropah - Croat - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Xarelto Kesatuan Eropah - Croat - EMA (European Medicines Agency)

xarelto

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Teynofor 245 mg filmom obložene tablete Croatia - Croat - HALMED (Agencija za lijekove i medicinske proizvode)

teynofor 245 mg filmom obložene tablete

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - tenofovirdizoproksilsukcinat - filmom obložena tableta - 245 mg - urbroj: jedna filmom obložena tableta sadrži 245 mg tenofovirdizoproksila (u obliku tenofovirdizoproksilsukcinata)